Enrollment Reached in Phase 3 Trials to Test Ublituximab in Relapsing MS Multiple Sclerosis News Today
TG Therapeutics announced it has reached target enrollment in the ULTIMATE I and II Phase 3 clinical trials assessing the use of ublituximab (TG-1101) to treat …